ACM
MBX

Aster Capital Management’s MBX Biosciences MBX Stock Holding History

Aster Capital Management’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.49K Buy
+172
New +$6.01K ﹤0.01% 667
2026
Q1 		– Sell
-265
Closed -$8.36K – 1422
2025
Q4 		$8.36K Buy
+265
New +$6.43K ﹤0.01% 777
2024
Q4 		– Sell
-1,810
Closed -$47K – 1600
2024
Q3 		$47K Buy
+1,810
New +$41.4K 0.01% 516

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Aster Capital Management's MBX Position: Q2 2026 in Review

Aster Capital Management opened a new position in MBX Biosciences (MBX) in Q2 2026: 172 shares worth $9.49K. The stake represents ﹤0.01% of the portfolio and ranks #667 among its holdings. This is a return to the name: Aster Capital Management previously reported a position in MBX as recently as Q4 2025.

Aster Capital Management first reported a position in MBX in Q3 2024 and has held it in 3 quarters since. The position peaked at $47K in Q3 2024. 173 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • Aster Capital Management held 172 shares of MBX Biosciences worth $9.49K as of Q2 2026.
  • MBX Biosciences was a new Aster Capital Management position in Q2 2026.
  • MBX Biosciences made up ﹤0.01% of Aster Capital Management's portfolio in Q2 2026, its #667 holding.
  • Aster Capital Management first reported a position in MBX Biosciences in Q3 2024 and has held it in 3 quarters since.
  • Aster Capital Management's MBX Biosciences position peaked at $47K in Q3 2024.
  • 173 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.